New test could match ovarian cancer patients to the right drug
NCT ID NCT03877796
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a device called a Drug Response Predictor (DRP) that uses a sample of a patient's tumor to see if it will respond to certain cancer drugs. The trial involves 60 people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the DRP can guide future treatment choices and also check if it correctly predicts past drug responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Drug Response Predictor (DRP) assay
What this could lead to
If successful, this could help doctors choose the right cancer drug for each patient, improving treatment effectiveness.
What could go wrong
This is an early-stage study with only 60 participants, and the predictor may not accurately forecast drug response in all cases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beatson West of Scotland Cancer Centre
ACTIVE_NOT_RECRUITINGGlasgow, Scotland, G12 0YN, United Kingdom
-
Dana-Farber Cancer Institute
COMPLETEDBoston, Massachusetts, 02215, United States
-
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital
ACTIVE_NOT_RECRUITINGLondon, United Kingdom
-
OU Health Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Swedish Center for Research and Innovation
RECRUITINGSeattle, Washington, 98122, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••